Quick verdict
Comparing Retatrutide and Tirzepatide: both have distinct mechanisms, FDA status, and use cases. Read the sections below to decide which may be right for you.
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Class | Triple Incretin Agonist | GIP/GLP-1 Receptor Agonist |
| FDA Status | Research Use | FDA Approved |
| Primary Uses | Weight Loss, Metabolic Health | Weight Loss, Type 2 Diabetes |
| Administration | Subcutaneous injection | Subcutaneous Injection |
| Typical Dosing | 1–2.5 mg initial dose, titrated every 4 weeks to 8–12 mg weekly maintenance | — |
| Evidence Level | — | — |
| Common Side Effects | — | — |
Compare verified research peptide suppliers with pricing, purity data, and trust signals.
Find a clinic that offers Retatrutide or Tirzepatide near you.
Browse Peptide Therapy ClinicsMyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.